Ultragenyx Pharma (RARE) Misses Q2 EPS by 16c, beats revenue

Ultragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($2.25), $0.16 worse than the analyst estimate of ($2.09). Revenue for the quarter came in at $108.3 million versus the consensus estimate of $107.1 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• UBS sees a negative catalyst ahead for Nike: Here’s what to watch
• Forgent Power Solutions, Inc. (FPS) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY27 Guidance
• Wall Street on Fed rate hike: 'As hawkish as it gets'